| P50 | author | Joanne E Mortimer | Q56826504 |
| P2093 | author name string | Katherine Oliver | |
| | Glenn Liu | |
| | Jennifer Heideman | |
| | Jamey Weichert | |
| | Michael Pishvaian | |
| | Scott Perlman | |
| | Lance Hall | |
| | Sam Joseph Lubner | |
| | Jacqueline Mullvain | |
| P2860 | cites work | Fluorescent Cancer-Selective Alkylphosphocholine Analogs for Intraoperative Glioma Detection | Q27346925 |
| | Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 |
| | Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. | Q30620931 |
| | Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab | Q33368796 |
| | Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues | Q33870440 |
| | Phospholipid ether analogs for the detection of colorectal tumors | Q34294317 |
| | Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients | Q34523261 |
| | A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety | Q34523934 |
| | Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma | Q34598460 |
| | Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects | Q34806351 |
| | Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents | Q35088190 |
| | Developments in the internal dosimetry of radiopharmaceuticals | Q35550407 |
| | Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer | Q35855096 |
| | Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. | Q37750797 |
| | Bone-targeting radiopharmaceuticals including radium-223. | Q38075735 |
| | A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells | Q40093876 |
| | Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. | Q40227228 |
| | Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues | Q40298705 |
| | Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis | Q40710187 |
| | Edelfosine is incorporated into rafts and alters their organization | Q46422474 |
| | Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation | Q46472923 |
| | Physical models and dose factors for use in internal dose assessment | Q47666272 |
| | Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop | Q48624737 |
| | Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy. | Q50880255 |
| | 131I-tositumomab therapy as initial treatment for follicular lymphoma. | Q54682444 |
| | Effect of anti-tumor ether lipids on ordered domains in model membranes | Q57360781 |
| | Cytotoxicity of an Anti-cancer Lysophospholipid through Selective Modification of Lipid Raft Composition | Q57372381 |
| P433 | issue | 10 | |
| P304 | page(s) | 483-489 | |
| P577 | publication date | 2015-11-04 | |
| P1433 | published in | Cancer Investigation | Q325953 |
| P1476 | title | A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies | |
| P478 | volume | 33 | |